News
The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal ...
The FDA announced a shift away from animal testing for drug approval, citing advanced alternatives like AI and organoids ...
The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies ...
One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual surgery required. Today, the company announced early data from animals and ...
The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...
The FDA is phasing out animal testing for monoclonal antibody therapies, embracing AI and human-based models. Read more here.
The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal ...
16h
Sportschosun on MSNApply AI model to drug development and phase out animal testing... FDA Announces Cost Reduction and Animal Welfare MeasuresThe U.S. Food and Drug Administration (FDA) announced on the 10th (local time) that it plans to replace animal testing with a new model based on artificial intelligence (AI). This approach, which will ...
A new multimodal tool combines a large language model with powerful graph-based AI models to efficiently find new, synthesizable molecules with desired properties, based on a user's queries in plain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results